9 completed, 2 terminated, 1 no longer available, 1 withdrawn. 7 Phase 1, 5 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 7 | Completed 6, Terminated 1 |
| Phase 2 | 5 | Completed 3, Terminated 1, Withdrawn 1 |
| Phase 3 | 1 | Completed 1 |
Follow marizomib: new trials by email Literature Review of marizomib trials Research Report on marizomib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Marizomib Central Nervous System (CNS) Marizomib, Pomalidomide, Dexamethasone - Multiple Myeloma, Multiple Myeloma in Relapse | Phase 2 | Withdrawn | Dana-Farber Cancer Institute | 2024-03-01 | 2024-07-16 | |
| Phase I Study of Marizomib + Panobinostat for Children With DIPG Marizomib, Panobinostat - Diffuse Intrinsic Pontine Glioma, Pediatric Brainstem Glioma | Phase 1 | Terminated | Dana-Farber Cancer Institute | 4 | 2020-08-10 | 2024-02-15 |
| Marizomib for Recurrent Low-Grade and Anaplastic Supratentorial, Infratentorial, and Spinal Cord Ependymoma Marizomib - Anaplastic Ependymoma, Ependymoma | Phase 2 | Terminated | National Cancer Institute (NCI) | 4 | 2020-01-22 | 2022-07-27 |
| Nab-sirolimus in Recurrent High Grade Glioma and Newly Diagnosed Glioblastoma nab-sirolimus, nab-sirolimus + temozolomide, nab-sirolimus + bevacizumab - High Grade Recurrent Glioma and Newly Diagnosed Glioblastoma | Phase 2 | Completed | Aadi Bioscience, Inc. | 62 | 2018-08-01 | 2023-11-07 |
| A Phase III Trial of With Marizomib in Patients With Newly Diagnosed Glioblastoma Marizomib, Temozolomide, radiotherapy - Newly Diagnosed Glioblastoma | Phase 3 | Completed | European Organisation for Research and Treatment of Cancer - EORTC | 749 | 2018-07-26 | 2025-07-01 |
| Study of Marizomib With Temozolomide and Radiotherapy in Patients With Newly Diagnosed Brain Cancer MRZ, TMZ, RT - Glioblastoma, Malignant Glioma | Phase 1 | Completed | Celgene | 66 | 2016-08-17 | 2021-04-19 |
| Stage 1: Marizomib + Bevacizumab in WHO Gr IV GBM; Stage 2: Marizomib Alone; Stage 3: Combination of Marizomib and Bevacizumab MRZ, BEV - Malignant Glioma, Glioblastoma | Phase 1 / Phase 2 | Completed | Celgene | 121 | 2015-04-15 | 2022-06-08 |
| Combination Study of Pomalidomide, Marizomib, and Low-Dose Dexamethasone in Relapsed and Refractory Multiple Myeloma pomalidomide, marizomib, low-dose dexamethasone - Multiple Myeloma in Relapse, Refractory Multiple Myeloma | Phase 1 | Completed | Celgene | 38 | 2014-06-05 | 2017-11-22 |
| NPI-0052 and Vorinostat in Patients With Non-small Cell Lung Cancer, Pancreatic Cancer, Melanoma or Lymphoma NPI-0052 (marizomib) + vorinostat - Non-Small Cell Lung Cancer, Pancreatic Cancer | Phase 1 | Completed | Celgene | 22 | 2008-03-01 | 2017-11-22 |
| Phase 1 Clinical Trial of NPI-0052 in Patients With Advanced Malignancies NPI-0052 on Days 1, 8, 15 every 28 days, NPI-0052 on Days 1, 4, 8, 11 every 21 days, Dexamethasone - Advanced Cancer | Phase 1 | Completed | Celgene | 86 | 2007-07-01 | 2017-11-22 |
| Phase 2 Clinical Trial of NPI-0052 in Patients With Relapsed or Relapsed/Refractory Multiple Myeloma MRZ 0.5 mg/m^2 - Multiple Myeloma | Phase 2 | Completed | Celgene | 15 | 2007-03-01 | 2017-12-19 |
| Phase 1 Clinical Trial of NPI-0052 in Patients With Advanced Solid Tumor Malignancies or Refractory Lymphoma NPI-0052 - Cancer, Lymphomas | Phase 1 | Completed | Celgene | 51 | 2006-05-01 | 2017-11-22 |
| Expanded Access for Marizomib Marizomib - Solid Tumor | No longer available | Celgene | 2020-11-25 |
Multiple Myeloma (5) · Glioblastoma (3) · Lymphoma (3) · Recurrence (3) · Brain Neoplasms (2) · Glioma (2) · Lymphoma, B-Cell, Marginal Zone (2) · Lymphoma, T-Cell, Cutaneous (2) · Neoplasms (2) · Carcinoma, Non-Small-Cell Lung (1) · Diffuse Intrinsic Pontine Glioma (1) · Disease Progression (1) · Ependymoma (1) · Gliosarcoma (1) · Leukemia (1)
Celgene (8) · Dana-Farber Cancer Institute (2) · Aadi Bioscience, Inc. (1) · European Organisation for Research and Treatment of Cancer - EORTC (1) · National Cancer Institute (NCI) (1)
United States (11) · Australia (3) · Canada (3) · Switzerland (2) · Austria (1) · Belgium (1) · Denmark (1) · France (1) · Germany (1) · Netherlands (1) · Norway (1) · Spain (1) · United Kingdom (1)
Steven D Reich, MD (5) · Clifton Mo, MD (1) · Ileana Elias, M.D. (1) · Ileana Elias, MD (1) · Katherine Warren, MD (1) · Mark R Gilbert, M.D. (1) · Patrick Roth (1)